​
​

Context Therapeutics Ownership | Who Owns Context Therapeutics?

OverviewForecastRevenueFinancialsChart

Context Therapeutics Ownership Summary

Context Therapeutics is owned by 103.78% institutional investors, 1.45% insiders. Vanguard group is the largest institutional shareholder, holding 28.20% of CNTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.52% of its assets in Context Therapeutics shares.

CNTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockContext Therapeutics103.78%1.45%-5.22%
SectorHealthcare Stocks 47.25%8.01%44.75%
IndustryBiotech Stocks 45.35%7.81%46.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.64M3.52%-483.00K
Franklin Biotechnology Discv A(acc)USD1.17M1.57%1.17M
Franklin Biotechnology Discovery A679.40K0.91%679.40K
Vanguard Institutional Extnd Mkt Idx Tr554.82K0.74%-721.15K
Fidelity Extended Market Index301.69K0.40%-132.25K
Belfund SICAV Belinvest Equity A USD Acc260.00K0.35%-
BlackRock Extended Equity Market K104.84K0.14%-45.00
Fidelity Total Market Index99.39K0.13%-244.00
NT Ext Equity Mkt Idx Fd - NL91.44K0.12%-
Northern Trust Extended Eq Market Idx78.17K0.10%-

Recent Insider Transactions

DateNameRoleActivityValue
Feb 21, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K
Feb 13, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K
Feb 06, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K
Jan 30, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K
Jan 23, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K

Insider Transactions Trends

DateBuySell
2024 Q3--
2024 Q2--
2024 Q1--
2023 Q2--
2023 Q16-

CNTX Ownership FAQ

Who Owns Context Therapeutics?

Context Therapeutics shareholders are primarily institutional investors at 103.78%, followed by 1.45% insiders and -5.23% retail investors. The average institutional ownership in Context Therapeutics's industry, Biotech Stocks , is 45.35%, which Context Therapeutics exceeds.

Who owns the most shares of Context Therapeutics?

Context Therapeutics’s largest shareholders are Vanguard group (4.5M shares, 28.20%), Deep track capital, lp (7.42M shares, 13.50%), and Nextech invest (7.42M shares, 13.50%). Together, they hold 55.20% of Context Therapeutics’s total shares outstanding.

Does Blackrock own Context Therapeutics?

Yes, BlackRock owns 5.33% of Context Therapeutics, totaling 851.7K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.71M$. In the last quarter, BlackRock increased its holdings by 851.7K shares, a 100.00% change.

Who is Context Therapeutics’s biggest shareholder by percentage of total assets invested?

Blue owl capital lp is Context Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.88% of its assets in 5.16M Context Therapeutics shares, valued at 10.35M$.

Who is the top mutual fund holder of Context Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Context Therapeutics shares, with 3.52% of its total shares outstanding invested in 2.64M Context Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools